Review of current etiopathogenetic data of Buerger disease;Przegla̧d danych etiopatogenetycznych o chorobie Buergera

Polski Merkuriusz Lekarski

Volumn 13, Issue 75, 2002, Pages 263-265

  Czarnacki, Maciej ^a   Zdrojowy, Krystyna ^a   Adamiec, Rajmund ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Blood vessel wall; Buerger's disease; Smoking; Thromboangiitis obliterans

Indexed keywords

ANTIELASTIN; COLLAGEN; ELASTIN; HLA A ANTIGEN; HLA A9 ANTIGEN; HLA B ANTIGEN; HLA B5 ANTIGEN; L SELECTIN; NICOTINE; PADGEM PROTEIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN; SELECTIN; THROMBOXANE A2; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; HLA ANTIGEN;

ARTERY SPASM; BLOOD CLOTTING; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; BUERGER DISEASE; COLLAGEN DISEASE; ENVIRONMENTAL FACTOR; ETIOLOGY; HEREDITY; HUMAN; IMMUNE COMPLEX DISEASE; IMMUNOPATHOLOGY; PATHOGENESIS; PHAGOCYTOSIS; SHORT SURVEY; SMOKING; THROMBOCYTE AGGREGATION; TISSUE PERFUSION; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; METABOLISM; PATHOLOGY; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM;

DIAGNOSIS, DIFFERENTIAL; ENDOTHELIUM, VASCULAR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA ANTIGENS; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; NICOTINE; RISK FACTORS; SMOKING; THROMBOANGIITIS OBLITERANS;

EID: 0036718346     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (40)

1. Aerbajinai W. i wsp.: HLA class II DNA typing in Buerger's disease. Int. J. Cardiol., 1996, 54 suppl., 197.
2. Allen E.V., Barker N.W., Heines E.A.: Peripheral vascular diseases. Philadelphia-London, 1962.
3. Bernard J.G. i wsp.: Le problėme étiologique des thromboangéites obliterantes du jéune adulte. Sem. d. Hop., 1959, 35, 327.
4. Bollinger A. i wsp.: Thromboangiitis obliterans. Diagnose und Therapie im Licht neuer immunologischer Befunde. Schweiz. Med. Wschr., 1979, 109, 537.
5. Buerger L.: The circulatory disturbances of the extremities, including gangrene, vasomotor and trophic disorders (ed.: Sanders). Philadelphia-London. 1924. W: Kaniak J.: Zakrzepowo-zarostowe zapalenie naczyn krwionośnych. PWN. Wrocław. 1955.
6. Colburn M.D., Moore W.S.: Buerger's disease. Heart Disease and Stroke, 1993, 424.
7. Corelli F.: Buerger's disease: cigarette smoker disease may always be cured by medical therapy alone. J. Cardiovasc. Surg., 1973, 14, 28.
8. Dwenger A., Tost P., Hole W.: Evaluation of elastaze and alpha1-proteinase uptake by polymorphonuclear leucocytes and evidence of an elastase - specific receptor. J. Clin. Chem. Clin. Biochem., 1986, 24, 299.
9. Gordon Z.L.: On Lesions of the adrenal cortex in thromboangiitis obliterans. Klin. Med., 1961, 39, 80.
10. Gulati S.M.: Immunological concept in etiology of thromboangiitis obliterans (Buerger's disease). Ind. J. Surg., 1980, 42, 223.
11. Hess H.: Rauchen und arterielle Durchblutungstörungen der Extremitaten. In: Nikotin. ed.: Schievelbein, Stottgart. Thieme, 1968, 193.
12. Higuchi K.: Abschätzung der adrenalomedullektomie zur Indikationsstellung bei peripheren Durchblutungsstörungen. Zentrallblatt für Chirurgie, 1964, 89, 53.
13. Hooten W.M., Bruns H.K., Hays J.T.: Inpatient treatment of severe nicotine dependence in a patient with thromboangiitis obliterans (Buerger's disease). Mayo - Clin. Proc., 1998, 73, 6, 529.
14. Horsch A.K. i wsp.: Antielastin Antikörper bei der Thromboangiitis obliterans. Verh. Dtsch. Ges. Inn. Med., 1977, 83, 1758.
15. Isner J.M. i wsp.: Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J. Vasc. Surg., 1998, 28 (6), 964.
16. Jaini R. i wsp.: Immunogenetic analysis of Buerger's disease in India. Int. J. Cardiol., 1998, 66, suppl. 1, 283.
17. Kaniak J.: Zakrzepowo-zarostowe zapalenie naczyń krwionośnych. PWN. Wrocław. 1955.
18. Kaniak J.: Zakrzepowo-zarostowe zapalenie naczyń. Choroba Buergera. W: Klinika i leczenie chorób naczyń obwodowych (red. Kaniak J.). PZWL. Warszawa. 1972, 101.
19. Kobayashi M. i wsp.: Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). J. Vac. Surg., 1999, 29, 3, 451.
20. Kowal-Gierczak B.: Współczesne pogla̧dy na patogenezȩ zakrzepowozaros-towego zapalenía naczyń (choroba Buergera). Pol. Arch. Med. Wewn., 1994, 5, 11, 437.
21. Kowal-Gierczak B., Kurzawska-Mielecka M., Czarnacki M.: Prostaglandyna E1 w leczeniu przewlekłego niedokrwienia kończyn. Pol. Arch. Med. Wewn., 1990, 84, 321.
22. Lambrecht R., Heinrich P.: Zur Pathogenese der Endangiitis obliterans. W: Thromboangiitis. Morbus Winiwarter-Buerger. Thieme Ver. Stuttgart. 1988, 54.
23. Leu H.J., Brunner U., Bollinger A.: Seitene gefässbeteiligungen bei Thromboangiitis obliterans. Symposium der Deutschen Gesellschaft für Angiologie. W: H.K. Breddin, C.M. Kirchmaier, P.C. Mauser: Angio Archiv., 1989, 18, 49.
24. McLoughlin G.A. i wsp.: Association of HLA-A9 and HLA-B5 with Buerger's disease. Brit. Med. J., 1976, 2, 1165.
25. Matheson N.R., Janoff A., Trans J.: Enzymatic oxidation of alpha1-proteinase inhibitor in abnormal tissue turnover. Mol. and Cell. Biochem., 1982, 45, 65.
26. Mils J.L.: Buerger's disease: current status. Vasc. Med. Rev., 1994, 5, 139.
27. Moncada S.: Prostacyclin and arterial wall biology PG12/ TXA2. Arteriosclerosis, 1982, 2, 193.
28. Nielubowicz J. i wsp.: Natural history of Buerger's disease. J. Cardiovas. Surg., 1998, 21, 529.
29. Othawa T. i wsp.: HLA Antigens in Thromboangiitis obliterans. JAMA, 1974, 8, 1128.
30. Olin J.W.: Thromboangiitis obliterans. Curr. Opin. Rheumatol., 1994, 6, 1, 44.
31. Reuter H.D.: Der Thrombocyt. 1988, Köln.
32. Robert L., Jacob M.P., Frances C.: Interaction between elastin and elastases and its role in the aging of the arterial wall, skin and other connective tissues. Mech. Aging. Develop., 1984, 28, 155.
33. Sasaki S. i wsp.: Current trends in thromboangiitis obliterans (Buerger's disease) in women. Am. J. Surg., 1999, 177, 4, 316.
34. Scharfetter K., Blasius S., Franke R.P.: Pathogenetic key position of thromboangiitis. The endothelial cell. serum dependent proliferation studies of endothelial cells in obliterative angiopathies. Vasa, 1986, 15, 34.
35. Sharma V. i wsp.: In vitro study of cell mediated immunity against tabacco in patients with thromboangiitis obliterans (TAO). Vasc. Med., 1985, 3, 35.
36. Szczeklik J., Szczeklik A., Niżankowski R.: Hemodynamic changes induced by prostacyclin in man. Br. Heart J., 1980, 44, 254.
37. Tervaert J.W., Kallenberg C.G.: Cell adhesion molecules in vasculitis. Current Opinion in Rheumatology, 1997, 9, 1, 16.
38. Virca G.D., Schnebli H.P.: The elastase and alpha1-proteinase inhibitor balance the lung. Schweiz. Med. Wschr., 1984, 114, 895.
39. Wysokiński W., Rabczyński J.: Późzmiany w ṡcianie aorty krȯlikȯw po immunizacji rozpuszczalna̧ elastyna̧. Spraw. Wrocł. Tow. Nauk., 1986, 41, 16.
40. Wysokiński,. W.: Peripheral necrosis of hind legs of rabbits immunized with elastin. Vasa, 1989, suppl. 27, 73.